Rohan Ramachandra Mahale
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Rohan Ramachandra Mahale has a total of 240 co-authors. Here are the top co-authors by number of shared publications:
Hansashree Padmanabha
Department of Neurology, National Institute of Mental Health & Neurosciences (NIMHANS), Bangalore, India
37 shared publicationsPooja Mailankody
Department of Neurology, National Institute of Mental Health & Neurosciences (NIMHANS), Bangalore, India
35 shared publicationsAnish Mehta
Department of Neurology, Ramaiah Medical College, Bengaluru, Karnataka, India
33 shared publicationsRangasetty Srinivasa
Department of Neurology, M S Ramaiah Medical College and Hospital, Bengaluru, Karnataka, India
19 shared publications- Nitish Kamble
Department of Neurology, National Institute of Mental Health & Neurosciences, Karnataka, India
15 shared publications - Pramod Kumar Pal
Department of Neurology, National Institute of Mental Health & Neurosciences, Karnataka, India
15 shared publications
Latest Publications
- 11 October 2026
- Published by Wiley in Movement Disorders Clinical Practice
Genotype–Phenotype Correlations in THAP1 ‐Associated Dystonia: A Multicentric Observational Study
Background: DYT‐ THAP1 is a recognized cause of early‐onset isolated dystonia. However, available data are largely derived from European cohorts, limiting understanding of genetic diversity, phenotype variability, and treatment response in underrepresented populations. Objectives: To characterize the clinical spectrum, genetic architecture, genotype–phenotype correlations, and treatment outcomes in Asian Indian patients with DYT‐ THAP1 . Methods: This multicentric, cross‐sectional study included patients harboring pathogenic or likely pathogenic THAP1 variants. Clinical features, neuroimaging, and treatment responses were systematically assessed. Genetic testing comprised whole‐exome sequencing, clinical exome sequencing, targeted gene panels, or Sanger sequencing. Variants were classified using ACMG criteria, and genotype–phenotype associations were analyzed. Results: Twenty‐six patients from 22 families were identified (17 males; mean age 29.4 ± 12.9 years). Median age at onset was 13.0 years (IQR 10.0–23.5), with 69.2% presenting before 20 years. Dystonia commonly involved the upper limbs (68%), cervical region (28%), and larynx (20%) at onset, with progression to generalized dystonia in 64%. Seventeen distinct heterozygous THAP1 variants were detected, of which 10 (58.8%) were novel. Loss‐of‐function variants affected 57.7% of patients and were associated with greater motor severity ( P = 0.023) and more frequent positive family history ( P = 0.019). Exon 2 variants were more frequent in patients with tremor ( P = 0.045). Conclusion: This study highlights the evolving mutational landscape of DYT‐ THAP1 beyond variants reported in Caucasian pedigrees and demonstrates novel, clinically relevant genotype–phenotype associations, underscoring the value of including underrepresented populations to bridge knowledge gaps in rare diseases.
- 11 October 2026
- Published by Wiley in Movement Disorders Clinical Practice
Genotype–Phenotype Correlations in THAP1 ‐Associated Dystonia: A Multicentric Observational Study
Background: DYT‐ THAP1 is a recognized cause of early‐onset isolated dystonia. However, available data are largely derived from European cohorts, limiting understanding of genetic diversity, phenotype variability, and treatment response in underrepresented populations. Objectives: To characterize the clinical spectrum, genetic architecture, genotype–phenotype correlations, and treatment outcomes in Asian Indian patients with DYT‐ THAP1 . Methods: This multicentric, cross‐sectional study included patients harboring pathogenic or likely pathogenic THAP1 variants. Clinical features, neuroimaging, and treatment responses were systematically assessed. Genetic testing comprised whole‐exome sequencing, clinical exome sequencing, targeted gene panels, or Sanger sequencing. Variants were classified using ACMG criteria, and genotype–phenotype associations were analyzed. Results: Twenty‐six patients from 22 families were identified (17 males; mean age 29.4 ± 12.9 years). Median age at onset was 13.0 years (IQR 10.0–23.5), with 69.2% presenting before 20 years. Dystonia commonly involved the upper limbs (68%), cervical region (28%), and larynx (20%) at onset, with progression to generalized dystonia in 64%. Seventeen distinct heterozygous THAP1 variants were detected, of which 10 (58.8%) were novel. Loss‐of‐function variants affected 57.7% of patients and were associated with greater motor severity ( P = 0.023) and more frequent positive family history ( P = 0.019). Exon 2 variants were more frequent in patients with tremor ( P = 0.045). Conclusion: This study highlights the evolving mutational landscape of DYT‐ THAP1 beyond variants reported in Caucasian pedigrees and demonstrates novel, clinically relevant genotype–phenotype associations, underscoring the value of including underrepresented populations to bridge knowledge gaps in rare diseases.
- 24 September 2026
- Published by Springer Nature in Journal of Neural Transmission
- p. 1-10
GNAL-associated dystonia: clinical spectrum, genetic features, and genotype–phenotype correlations
- 24 September 2026
- Published by Springer Nature in Journal of Neural Transmission
- p. 1-10
GNAL-associated dystonia: clinical spectrum, genetic features, and genotype–phenotype correlations
- 27 August 2026
- Published by Springer Nature in neurogenetics
- Vol. 27 (1) , 59
THG1L- associated early childhood-onset cerebellar ataxia with atrophy and developmental delay
- 27 August 2026
- Published by Springer Nature in neurogenetics
- Vol. 27 (1) , 59
THG1L- associated early childhood-onset cerebellar ataxia with atrophy and developmental delay
- Open Access
- 4 August 2026
- Published by Wolters Kluwer Health in Annals of Indian Academy of Neurology
- Vol. 29 (5) , 750-755
Fatigue in Parkinson’s Disease: A Cross-Sectional Study of Prevalence and Clinical Correlates
Background and Objectives: Fatigue is a non-motor symptoms (NMS) of Parkinson’s disease (PD). The study aimed to determine the frequency and severity of fatigue, its predictors, and its impact on quality of life. Methods: We included 150 patients with PD. The Fatigue Severity Scale (FSS) and the Parkinson Fatigue Scale–16 (PFS-16) were used to assess the presence and severity of fatigue. Results: The frequency of fatigue was 46%, predominantly of mild severity. The mean FSS score was 33.3 ± 10.3. Patients with fatigue were older, had a longer disease duration, received higher levodopa doses, and had greater motor and NMS severity. Anxiety and depression scores were higher, along with a greater frequency of excessive daytime sleepiness and sleep disturbances. Fatigue had a negative impact on quality of life. Multivariate analysis identified disease duration, motor severity, and depression as independent predictors of fatigue. Conclusions: Fatigue is a frequent yet underrecognized NMS in PD. Nearly half of the patients experienced fatigue, mostly of mild severity, and it was associated with longer disease duration, greater disease severity, mood disturbances, sleep-related symptoms, and reduced quality of life.
- 4 August 2026
- Published by Wolters Kluwer Health in Annals of Indian Academy of Neurology
- Vol. 29 (5) , 750-755
Open AccessFatigue in Parkinson’s Disease: A Cross-Sectional Study of Prevalence and Clinical Correlates
Background and Objectives: Fatigue is a non-motor symptoms (NMS) of Parkinson’s disease (PD). The study aimed to determine the frequency and severity of fatigue, its predictors, and its impact on quality of life. Methods: We included 150 patients with PD. The Fatigue Severity Scale (FSS) and the Parkinson Fatigue Scale–16 (PFS-16) were used to assess the presence and severity of fatigue. Results: The frequency of fatigue was 46%, predominantly of mild severity. The mean FSS score was 33.3 ± 10.3. Patients with fatigue were older, had a longer disease duration, received higher levodopa doses, and had greater motor and NMS severity. Anxiety and depression scores were higher, along with a greater frequency of excessive daytime sleepiness and sleep disturbances. Fatigue had a negative impact on quality of life. Multivariate analysis identified disease duration, motor severity, and depression as independent predictors of fatigue. Conclusions: Fatigue is a frequent yet underrecognized NMS in PD. Nearly half of the patients experienced fatigue, mostly of mild severity, and it was associated with longer disease duration, greater disease severity, mood disturbances, sleep-related symptoms, and reduced quality of life.
- 29 July 2026
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 126 (6) , 2197-2199
FAT2-associated early-onset cerebellar ataxia: report of novel phenotype and variant
- 29 July 2026
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 126 (6) , 2197-2199
FAT2-associated early-onset cerebellar ataxia: report of novel phenotype and variant
- 17 July 2026
- Published by Wolters Kluwer Health in Annals of Indian Academy of Neurology
Non-Hepatitis C-Associated Cryoglobulinemic Vasculitic Neuropathy
Was not provided for this article.
- 17 July 2026
- Published by Wolters Kluwer Health in Annals of Indian Academy of Neurology
Non-Hepatitis C-Associated Cryoglobulinemic Vasculitic Neuropathy
Was not provided for this article.
- 1 July 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (7)
Hypogonadotrophic hypogonadism in GBA2 associated spastic paraplegia type 46 (SPG46): a phenotypic expansion
- 1 July 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (7)
Hypogonadotrophic hypogonadism in GBA2 associated spastic paraplegia type 46 (SPG46): a phenotypic expansion
- 29 June 2026
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 133 (9) , 2599-2607
FBXO7- associated parkinsonism: clinical, genetic, and radiological insights from a case report and literature review
Background Variants in the FBXO7 gene are a recognized cause of juvenile-onset autosomal recessive parkinsonism (PARK15) with a heterogeneous phenotype. There is limited number of reported cases in the literature. Objective To report a 19-year-old Indian man with juvenile-onset parkinsonism harbouring a novel FBXO7 variant and to review the published literature on FBXO7-associated parkinsonism/parkinsonism-pyramidal syndrome, focusing on the clinical, imaging, and genetic spectrum and possible genotype–phenotype correlations. Methods We evaluated an Indian male with FBXO7-associated juvenile parkinsonism and reviewed previously published cases from the literature to assess the clinical, imaging, and genetic spectrum. Results A total of 32 cases of FBXO7-associated parkinsonism, including our patient, were identified. The median age at onset was 17 years, median age at presentation was 28 years, with slight male predominance and a median disease duration of 5 years. Symmetrical juvenile-onset parkinsonism with tremor and postural instability was the commonest presentation. Dementia, dystonia, pyramidal signs, and gaze abnormalities were less frequent associated features. Most patients showed levodopa responsiveness, although motor complications and psychiatric adverse effects were common. Neuroimaging findings were heterogeneous, ranging from cortical atrophy to pallidal hypointensity and presynaptic dopaminergic deficits on dopamine transporter imaging. Twenty variants were identified, with the homozygous nonsense variant c.1492 C > T (p.Arg498*) being the most frequently reported. Conclusion FBXO7-associated parkinsonism typically presents as symmetrical juvenile-onset levodopa-responsive parkinsonism, although early-onset parkinsonism is known. Dementia, dystonia, and pyramidal signs are less frequent associated features. FBXO7 variants should be considered in patients with symmetrical juvenile/early-onset parkinsonism, especially when accompanied by levodopa-induced psychiatric adverse effects.
- 29 June 2026
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 133 (9) , 2599-2607
FBXO7- associated parkinsonism: clinical, genetic, and radiological insights from a case report and literature review
Background Variants in the FBXO7 gene are a recognized cause of juvenile-onset autosomal recessive parkinsonism (PARK15) with a heterogeneous phenotype. There is limited number of reported cases in the literature. Objective To report a 19-year-old Indian man with juvenile-onset parkinsonism harbouring a novel FBXO7 variant and to review the published literature on FBXO7-associated parkinsonism/parkinsonism-pyramidal syndrome, focusing on the clinical, imaging, and genetic spectrum and possible genotype–phenotype correlations. Methods We evaluated an Indian male with FBXO7-associated juvenile parkinsonism and reviewed previously published cases from the literature to assess the clinical, imaging, and genetic spectrum. Results A total of 32 cases of FBXO7-associated parkinsonism, including our patient, were identified. The median age at onset was 17 years, median age at presentation was 28 years, with slight male predominance and a median disease duration of 5 years. Symmetrical juvenile-onset parkinsonism with tremor and postural instability was the commonest presentation. Dementia, dystonia, pyramidal signs, and gaze abnormalities were less frequent associated features. Most patients showed levodopa responsiveness, although motor complications and psychiatric adverse effects were common. Neuroimaging findings were heterogeneous, ranging from cortical atrophy to pallidal hypointensity and presynaptic dopaminergic deficits on dopamine transporter imaging. Twenty variants were identified, with the homozygous nonsense variant c.1492 C > T (p.Arg498*) being the most frequently reported. Conclusion FBXO7-associated parkinsonism typically presents as symmetrical juvenile-onset levodopa-responsive parkinsonism, although early-onset parkinsonism is known. Dementia, dystonia, and pyramidal signs are less frequent associated features. FBXO7 variants should be considered in patients with symmetrical juvenile/early-onset parkinsonism, especially when accompanied by levodopa-induced psychiatric adverse effects.
- 24 June 2026
- Published by Cambridge University Press (CUP) in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
- p. 1-8
Chronology of Non-Motor Symptoms in 100 Patients with Advanced PD of 10 Years’ Duration: Pre- versus Post-Motor Period
Background: Parkinson’s disease (PD) is characterized by motor and non-motor symptoms (NMS) due to alpha-synuclein aggregation in the central and peripheral nervous system. There is limited data on the temporal evolution of NMS in patients with long-standing PD. Objective: To elucidate the chronology of the evolution of NMS in patients with long-standing PD. Methods: This single-centre cross-sectional study was conducted at a tertiary care centre from May 2023 to December 2024. Patients with clinically diagnosed idiopathic PD of at least 10 years” duration were recruited, and the chronology of the evolution of NMS was characterized. Results: One hundred patients with PD (68% male) were recruited, with a mean age at assessment of 58.8 ± 9.7 years, an age at onset of 45.7 ± 10.1 years and a disease duration of 13.2 ± 3.3 years. Six percent of the patients did not develop any NMS despite the long duration of the illness. Rapid eye movement sleep behavioural disorder (RBD) (63%) was the most frequent NMS, followed by constipation (59%) and urinary dysfunction (55%). Pre-motor onset of NMS was present in 24% of the patients, with RBD (8%) and constipation (8%) being the most frequent. Post-motor onset was observed in 70% of cases. Based on the pre- or post-motor onset of RBD, patients were classified into two subtypes: body-first (8%) and brain-first (84%) PD subtypes. Conclusion: This study highlights the distinct trajectories of NMS evolution in PD. While the majority developed at least one NMS, the occurrence of pre-motor NMS was present in about one-fourth. The body-first subtype, characterized by pre-motor RBD, was distinctly uncommon.
- 24 June 2026
- Published by Cambridge University Press (CUP) in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
- p. 1-8
Chronology of Non-Motor Symptoms in 100 Patients with Advanced PD of 10 Years’ Duration: Pre- versus Post-Motor Period
Background: Parkinson’s disease (PD) is characterized by motor and non-motor symptoms (NMS) due to alpha-synuclein aggregation in the central and peripheral nervous system. There is limited data on the temporal evolution of NMS in patients with long-standing PD. Objective: To elucidate the chronology of the evolution of NMS in patients with long-standing PD. Methods: This single-centre cross-sectional study was conducted at a tertiary care centre from May 2023 to December 2024. Patients with clinically diagnosed idiopathic PD of at least 10 years” duration were recruited, and the chronology of the evolution of NMS was characterized. Results: One hundred patients with PD (68% male) were recruited, with a mean age at assessment of 58.8 ± 9.7 years, an age at onset of 45.7 ± 10.1 years and a disease duration of 13.2 ± 3.3 years. Six percent of the patients did not develop any NMS despite the long duration of the illness. Rapid eye movement sleep behavioural disorder (RBD) (63%) was the most frequent NMS, followed by constipation (59%) and urinary dysfunction (55%). Pre-motor onset of NMS was present in 24% of the patients, with RBD (8%) and constipation (8%) being the most frequent. Post-motor onset was observed in 70% of cases. Based on the pre- or post-motor onset of RBD, patients were classified into two subtypes: body-first (8%) and brain-first (84%) PD subtypes. Conclusion: This study highlights the distinct trajectories of NMS evolution in PD. While the majority developed at least one NMS, the occurrence of pre-motor NMS was present in about one-fourth. The body-first subtype, characterized by pre-motor RBD, was distinctly uncommon.
- 4 May 2026
- Published by Springer Nature in The Cerebellum
- Vol. 25 (3) , 70
Clinical and Genetic Profile of Gordon-Holmes Syndrome: A Review of Published Cases
Gordon Holmes syndrome (GHS, MIM 212840) is an autosomal recessive disorder with a clinical manifestation of cerebellar ataxia, dementia and hypogonadotropic hypogonadism. To describe the clinical and genetic profile of patients with GHS reported worldwide with genotype-phenotype correlation. This is a review of reported cases of GHS based on the different genetic variant worldwide. We report 2 patients of GHS due to variant in the RNF216 gene. There was total 29 reported cases of GHS with RNF216 variants, 9 cases with PNPLA6 variants, and 5 with STUB1 variant. There was male predominance in the RNF216 and PNPLA6 variants. The median age at onset was lower and duration of illness was longer in STUB1 variants. Cerebellar ataxia and dysarthria were seen in all variants. Dementia, chorea and psychiatric disturbances were common in RNF216 variants. Seizures were seen only in STUB1 variants. Hypogonadotrophic hypogonadism were seen in all variants. Brain magnetic resonance imaging showed signal changes in the white matter apart from the cerebellar and cerebral atrophy in RNF216 variants. Missense, frameshift and non-sense variants were common in RNF216 and missense variants were common in PNPLA6 and STUB1. The phenotypic and genotypic presentation of GHS is heterogeneous with variants in the RNF216 representing majority of GHS cases.
- 4 May 2026
- Published by Springer Nature in The Cerebellum
- Vol. 25 (3) , 70
Clinical and Genetic Profile of Gordon-Holmes Syndrome: A Review of Published Cases
Gordon Holmes syndrome (GHS, MIM 212840) is an autosomal recessive disorder with a clinical manifestation of cerebellar ataxia, dementia and hypogonadotropic hypogonadism. To describe the clinical and genetic profile of patients with GHS reported worldwide with genotype-phenotype correlation. This is a review of reported cases of GHS based on the different genetic variant worldwide. We report 2 patients of GHS due to variant in the RNF216 gene. There was total 29 reported cases of GHS with RNF216 variants, 9 cases with PNPLA6 variants, and 5 with STUB1 variant. There was male predominance in the RNF216 and PNPLA6 variants. The median age at onset was lower and duration of illness was longer in STUB1 variants. Cerebellar ataxia and dysarthria were seen in all variants. Dementia, chorea and psychiatric disturbances were common in RNF216 variants. Seizures were seen only in STUB1 variants. Hypogonadotrophic hypogonadism were seen in all variants. Brain magnetic resonance imaging showed signal changes in the white matter apart from the cerebellar and cerebral atrophy in RNF216 variants. Missense, frameshift and non-sense variants were common in RNF216 and missense variants were common in PNPLA6 and STUB1. The phenotypic and genotypic presentation of GHS is heterogeneous with variants in the RNF216 representing majority of GHS cases.